RBD-8088, a BBB-penetrating oligonucleotide with efficacy in glioblastoma models

Sep. 27, 2024

Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.

BioWorld Science Conferences European Society for Medical Oncology Cancer Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 17, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...